generation run 2026-04-26
61 min completedmodel pipeline-v5plan not recordedrun/18be5608…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- safety_data_gap
- class_inference
- sparse_evidence
Reproduce
- inputs
- 35 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
21 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | PubMed | flubromazolam toxicology overdose case report | 2 | 2 | Key clinical toxicology evidence |
| 2 | PubMed | flubromazolam pharmacology benzodiazepine | 15 | 5 | Prioritized substance-specific studies and reviews with flubromazolam-specific data |
| 3 | ClinicalTrials.gov · absence | flubromazolam | 0 | 0 | Confirms no clinical development |
| 4 | PubMed · absence | flubromazolam GABA receptor binding affinity Ki | 0 | 0 | Absence documented - will note as gap |
| 5 | PubChem | flubromazolam | 1 | 1 | Primary chemical identity verification |
| 6 | OpenAlex | flubromazolam designer benzodiazepine | 10 | 5 | High-citation landmark papers covering flubromazolam |
| 7 | PubMed | flubromazolam metabolism metabolites CYP | 2 | 2 | Primary metabolism data for flubromazolam |
| 8 | OpenAlex | flubromazolam overdose death forensic toxicology | 10 | 4 | Landmark forensic/toxicology papers with flubromazolam data |
| 9 | ClinicalTrials.gov · absence | flubromazolam | 0 | 0 | Absence confirmed |
| 10 | WebSearch (Google) | flubromazolam legal status UK Misuse of Drugs Act scheduling Europe 2023 2024 | 10 | 2 | International legal status |
| 11 | WebSearch (Google) | flubromazolam DEA Schedule 1 scheduling date controlled substance analog | 10 | 3 | Legal status verification |
| 12 | PubMed | Moosmann flubromazolam pharmacokinetics self-experiment half-life | 1 | 1 | Primary human pharmacokinetic data |
| 13 | WebSearch | flubromazolam Canada scheduling controlled analogue Australia | 10 | 3 | International legal status research |
| 14 | WHO ECDD | WHO ECDD 43rd Critical Review Flubromazolam | 1 | 0 | Critical regulatory document |
| 15 | Crossref DOI verification | 10.1007/s11419-015-0277-6 | 1 | 1 | Key early characterization paper for flubromazolam |
| 16 | Multiple | flubromazolam synthesis history patent 1978 EP 0072029 | 5 | 1 | Historical synthesis context |
| 17 | PubMed | flubromazolam OR 8-bromo-6-(2-fluorophenyl)-1-methyl benzodiazepine | 10 | 3 | New forensic epidemiology and clinical management papers |
| 18 | PubMed | benzodiazepine opioid interaction synergistic respiratory depression pharmacodynamic | 5 | 2 | Mechanism of opioid+benzodiazepine interaction relevant to flubromazolam lethality risk |
| 19 | PubChem CID 21930924 | flubromazolam chemical identity | 1 | 1 | Chemical identity verification completed |
| 20 | WHO ECDD 43rd | — | 1 | 1 | Key regulatory/scientific authority document |
| 21 | WebSearch / Federal Register | flubromazolam DEA Schedule I permanent 2026 | 5 | 3 | Legal status confirmation |
95 claims by section — every cited sentence, checked against its source
safety35 · 29 ok
The first published case report described severe intoxication with prolonged coma, hypotension, and rhabdomyolysis, establishing that flubromazolam can produce life-threatening effects even in single-drug exposure.supported
Recreational use may be a cause of prolonged, severe intoxication associated with coma, hypotension, and rhabdomyolysis. 15563650.2015.1112907
The primary acute risk arises from three converging factors: (1) the sub-milligram active dose range makes accurate dosing extremely difficult in unregulated preparations, (2) amnesia and delusions of sobriety promote compulsive redosing, and (3) synergistic respiratory depression with co-administered opioids or alcohol drives nearly all documented fatalities.partially supported
compounds like clonazolam or flubromazolam can cause strong sedation and amnesia at oral doses as low as 0.5 mg wps.20236
Victoria, Australia (2018–2022): Flubromazolam detected in 12 of 133 novel benzodiazepine-associated deaths; all cases involved co-administration of at least one other CNS-active drug.supported
133 novel BZD deaths in Victoria 2018-2022. Flubromazolam in 12 cases. All deaths involved other CNS active drugs. bkae075
North Carolina (2020–2022): Flubromazolam detected in counterfeit alprazolam, oxycodone, and hydrocodone pills associated with deaths; decedents aged 16–69.supported
Flubromazolam detected in counterfeit alprazolam/oxycodone/hydrocodone pills. Decedents ages 16-69. bkae027
San Francisco (2019–2023): Flubromazolam identified in designer benzodiazepine fatalities before bromazolam achieved market dominance.supported
4-year analysis of NBD-related deaths in San Francisco. Flubromazolam was among NBDs detected before bromazolam surge. add.16520
England and Wales: Flubromazolam co-detected in 48% of a 96-case bromazolam coronial series.partially supported
96 bromazolam coronial cases. 48% also had at least one other designer BZD (etizolam, flualprazolam, flubromazolam, flubromazepam). j.forsciint.2023.111891
International: Brunetti and colleagues identified flubromazolam as one of the top three designer benzodiazepines in adverse events, deaths, and DUID cases reported to UNODC (2019–April 2020).supported
Flubromazolam among top substances in adverse events and deaths. 2019-April 2020: DBZD identified in 48% postmortem and 83% DUID cases (UNODC). Flubromazolam, flualprazolam, etizolam most frequently detected. ph14060560
US CDC surveillance: Illicit benzodiazepine-involved deaths increased 519.6% from 2019 to mid-2020; 92.7% involved opioids.supported
Illicit BZD deaths increased 519.6% 2019-2020. 92.7% with opioids. mmwr.mm7034a2
Claim in safety — inconclusiveinconclusiveworking →
Flubromazolam has been detected as an adulterant in unregulated opioid supplies and in counterfeit prescription opioid and benzodiazepine pillssupported
NPS BZDs found in Vancouver drug supply from mid-2018. Rise concordant with atypical overdose outbreak from benzodiazepine adulteration of unregulated opioids. j.drugpo.2021.103169
Flubromazolam has been detected as an adulterant in unregulated opioid supplies and in counterfeit prescription opioid and benzodiazepine pillssupported
Flubromazolam detected in counterfeit alprazolam/oxycodone/hydrocodone pills. bkae027
Claim in safety — inconclusiveinconclusiveworking →
Disinhibition and loss of behavioural control are reported in user accounts and are consistent with the compound's documented involvement in impaired driving casessupported
Also: anxiolysis, muscle-relaxing effects, euphoria, loss of control, severe withdrawals. neurolint14030053
Claim in safety — inconclusiveinconclusiveworking →
Disinhibition and loss of behavioural control are reported in user accounts and are consistent with the compound's documented involvement in impaired driving casessupported
Flubromazolam detected among 11 DBZDs. Driving behavior consistent with CNS depressant effects. bkad036
The combination of amnesia, disinhibition, and high potency has led to flubromazolam's identification among designer benzodiazepines with drug-facilitated sexual assault risk.supported
DBZDs active at low doses, fast onset, easily administered orally — ideal DFSA candidates. Reviews toxicological analysis and PK in DFSA context. bkac017
Edinoff and colleagues describe "rapid development of tolerance" as among the most commonly noted effects by recreational userssupported
Effects: heavy hypnosis and sedation, long-lasting amnesia, rapid development of tolerance. neurolint14030053
The molecular mechanism involves downregulation of GABA-A receptor subunits and compensatory sensitisation of excitatory glutamatergic (NMDA and AMPA) neurotransmissionsupported
Tolerance mediated by GABA-A subunit downregulation and glutamatergic sensitization. ijms27031430
The molecular mechanism involves downregulation of GABA-A receptor subunits and compensatory sensitisation of excitatory glutamatergic (NMDA and AMPA) neurotransmissionsupported
Tolerance mediated by GABA-A subunit downregulation and glutamatergic sensitization. s12991-025-00627-0
Butler and colleagues reported a case of seizure following abrupt cessation of illicit benzodiazepines including flubromazolam, noting that symptom-based management was required because no established long-acting benzodiazepine equivalence dose exists for flubromazolamsupported
seizure from abrupt cessation... Flubromazolam has no approved long-acting BZD equivalents; symptom-based diazepam management required. bcr-2025-266077
Edinoff and colleagues documented "severe withdrawals" in recreational users.supported
Also: anxiolysis, muscle-relaxing effects, euphoria, loss of control, severe withdrawals. neurolint14030053
Synergistic respiratory depression occurs via co-located μ-opioid and GABA-A receptors on medullary respiratory rhythm-generating neuronssupported
GABA-A activation suppresses respiration in medullary respiratory centres. Combining opioids with BZDs induces synergistic... depression of respiration. bcpt.12655
Animal models confirm exacerbated respiratory depression (decreased PaO₂, increased PaCO₂) with opioid–benzodiazepine co-administrationsupported
BZD+opioid co-administration caused further decreases in PaO2 and increases in PaCO2 consistent with exacerbated respiratory depression. j.toxrep.2020.01.008
US surveillance data show 92.7% of illicit benzodiazepine-involved deaths involved co-administered opioids, predominantly illicitly manufactured fentanyls.partially supported
Illicit BZD deaths increased 519.6% 2019-2020. 92.7% with opioids. mmwr.mm7034a2
Three factors make the flubromazolam–opioid interaction particularly hazardous: (1) naloxone does not reverse benzodiazepine-mediated respiratory depression, (2) flubromazolam has been documented as an adulterant in unregulated opioid supplies, and (3) flubromazolam's long half-life (10–20 hours) may exceed the duration of naloxone action, requiring extended observation or repeat dosing.partially supported
NPS BZDs found in Vancouver drug supply from mid-2018. Rise concordant with atypical overdose outbreak from benzodiazepine adulteration of unregulated opioids. j.drugpo.2021.103169
This combination is documented in polydrug fatality case series.supported
133 novel BZD deaths in Victoria 2018-2022. Flubromazolam in 12 cases. All deaths involved other CNS active drugs. bkae075
In English and Welsh coronial cases, flubromazolam co-occurred with at least one other designer benzodiazepine in 48% of cases.partially supported
96 bromazolam coronial cases. 48% also had at least one other designer BZD (etizolam, flualprazolam, flubromazolam, flubromazepam). j.forsciint.2023.111891
CYP3A4 inhibitors (itraconazole, ketoconazole, voriconazole, ritonavir, clarithromycin, grapefruit juice) are expected to substantially increase flubromazolam plasma concentrations based on CYP3A4/5 as the primary metabolic pathway.supported
Main metabolic pathway: hydroxylation at α- and/or 4-position mediated by CYP3A4 and CYP3A5 dta.2146
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
CYP3A4 inhibitor co-administration is a relative contraindication: potent CYP3A4 inhibitors would be expected to substantially increase flubromazolam exposure given CYP3A4/5 as the primary metabolic pathway.supported
Main metabolic pathway: hydroxylation at α- and/or 4-position mediated by CYP3A4 and CYP3A5 dta.2146
Claim in safety — inconclusiveinconclusiveworking →
Epilepsy or seizure disorders: While benzodiazepines are anticonvulsant during use, abrupt withdrawal from flubromazolam can precipitate seizuressupported
Case of male in early 20s with seizure from abrupt cessation of multiple illicit substances including bromazolam/flubromazolam bcr-2025-266077
A systematic review found flumazenil associated with 3.81× higher serious adverse events (supraventricular arrhythmia, seizures) compared to placebo in benzodiazepine overdosesupported
SAEs 3.81x higher. Most common SAEs: supraventricular arrhythmia and convulsions. bcpt.12434
Pre-hospital intramuscular flumazenil may be considered in naloxone-unresponsive coma with suspected benzodiazepine involvement.supported
Flumazenil rarely used due to seizure risk; risk-benefit may favor pre-hospital IM use. bcpt.70007
pharmacokinetic-detail12 · 8 ok
All human data derive from a single-subject oral self-experiment (0.5 mg):supported
Self-experiment with 0.5 mg dta.2203
Canfield, Kisor, and Sprague compared the pharmacokinetics of flubromazolam, flualprazolam, and alprazolam in Sprague-Dawley rats (2 mg/kg subcutaneous)supported
Rat model (2 mg/kg SC). Flubromazolam displayed significant 2-fold increases in volume of distribution and clearance compared to alprazolam. j.taap.2023.116459
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Noble and colleagues characterised flubromazolam metabolism in vitro using pooled human liver microsomes and recombinant CYP enzymes:supported
Main metabolic pathway: hydroxylation at α- and/or 4-position mediated by CYP3A4 and CYP3A5 dta.2146
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
In vivo metabolite detection in the self-experiment confirmed the in vitro predictions: α-hydroxy-flubromazolam was the main urinary metabolite, accompanied by its glucuronide conjugate and the parent N-glucuronide.supported
Primary metabolite: mono-hydroxylated metabolite. Glucuronides also detected. dta.2203
CYP3A4 and CYP3A5 as the sole identified Phase I metabolic enzymes create substantial interaction potentialsupported
Main metabolic pathway: hydroxylation at α- and/or 4-position mediated by CYP3A4 and CYP3A5 dta.2146
Flubromazolam shows high cross-reactivity in standard benzodiazepine immunoassays (CEDIA, EMIT II Plus, HEIA, KIMS II), though serum immunoassay may be negative while urine immunoassay is positivesupported
Flubromazolam shows high cross-reactivity in all four immunoassays. KIMS II and CEDIA showed highest reactivity. Negative serum but positive urine results consistent with Huppertz 2018 findings. dta.2003
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Confirmatory identification and quantitation require LC-MS/MSsupported
LC-MS/MS advances. Genetic polymorphisms and drug interactions need further research. aiht-2023-74-3771
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
A validated hair analysis method exists with detection confirmed at least 2 weeks post-single-dose exposuresupported
Validated LC-MS/MS hair method for 17 designer BZDs including flubromazolam. LOQ 5-25 pg/mg. Applied to 19 authentic cases. bkac044
pharmacology11 · 9 ok
Benzodiazepines bind to the extracellular interface between α and γ subunits of pentameric GABA-A receptors, enhancing chloride ion conductance in response to endogenous GABA binding and thereby potentiating inhibitory neurotransmission throughout the central nervous systemsupported
Benzodiazepine site at alpha/gamma subunit interface. Subtype selectivity structural basis. s41467-022-32212-4
Benzodiazepines bind to the extracellular interface between α and γ subunits of pentameric GABA-A receptors, enhancing chloride ion conductance in response to endogenous GABA binding and thereby potentiating inhibitory neurotransmission throughout the central nervous systemsupported
BZDs act as GABA-A receptor positive allosteric modulators. s12991-025-00627-0
The compound's exceptional potency — pharmacological effects at oral doses of 0.5 mg — is inferred from its triazolobenzodiazepine structure, clinical case observations, and quantitative structure-activity relationship (QSAR) modelling that predicts triazolobenzodiazepines as the most potent subclass of designer benzodiazepines.supported
QSAR model to predict GABA-A receptor binding of newly emerging benzodiazepines including flubromazolam. Triazolobenzodiazepines predicted to be among the most potent group. j.scijus.2017.12.004
Moosmann, King, and Auwärter identified flubromazolam and clonazolam as capable of producing "strong sedation and amnesia at oral doses as low as 0.5 mg," placing them among the highest-potency designer benzodiazepinessupported
compounds like clonazolam or flubromazolam can cause strong sedation and amnesia at oral doses as low as 0.5 mg wps.20236
The only published human pharmacokinetic data derive from a single self-experiment by Huppertz, Moosmann, and Auwärter, in which one of the authors ingested a 0.5 mg oral dosesupported
Self-experiment with 0.5 mg: terminal elimination half-life 10-20h, peak serum 8 ng/mL at 8h dta.2203
Claim in pharmacology — inconclusiveinconclusiveworking →
In vitro metabolism studies in pooled human liver microsomes and recombinant CYP enzymes established CYP3A4 and CYP3A5 as the primary metabolic enzymes, catalysing hydroxylation at the α- and/or 4-positionssupported
Main metabolic pathway: hydroxylation at α- and/or 4-position mediated by CYP3A4 and CYP3A5 dta.2146
Predicted hepatic clearance was low (CL_H 0.42–0.43 mL/min/kg) across both well-stirred and parallel-tube models, consistent with the compound's long elimination half-lifesupported
Predicted hepatic clearance 0.42-0.43 mL/min/kg (low). dta.2146
Claim in pharmacology — inconclusiveinconclusiveworking →
The primary urinary targets for forensic detection are α-hydroxy-flubromazolam, its glucuronide conjugate, and the N-glucuronide of the parent compound — metabolites confirmed both in vitro and in the single-subject in vivo study.supported
Primary metabolite: mono-hydroxylated metabolite. Glucuronides also detected. dta.2203
Co-administration of potent CYP3A4 inhibitors (azole antifungals, ritonavir, clarithromycin, grapefruit juice) would be expected to meaningfully increase flubromazolam exposure and prolong its duration of action.supported
Main metabolic pathway: hydroxylation at α- and/or 4-position mediated by CYP3A4 and CYP3A5 dta.2146
summary9 · 9 ok
The terminal elimination half-life is estimated at 10–20 hours.supported
terminal elimination half-life 10-20h dta.2203
It appeared on online research chemical markets from 2014 and was rapidly flagged as a public health concern due to sub-milligram active doses that are difficult to measure accurately in unregulated preparationspartially supported
Flubromazolam offered online from 2014 dta.2203
It appeared on online research chemical markets from 2014 and was rapidly flagged as a public health concern due to sub-milligram active doses that are difficult to measure accurately in unregulated preparationssupported
compounds like clonazolam or flubromazolam can cause strong sedation and amnesia at oral doses as low as 0.5 mg. Notes challenges with immunochemical detection and legal scheduling. wps.20236
The entire published human pharmacokinetic dataset derives from a single researcher self-experiment.supported
Self-experiment with 0.5 mg: terminal elimination half-life 10-20h, peak serum 8 ng/mL at 8h, urine detection up to 8 days dta.2203
As a positive allosteric modulator of the GABA-A receptor, flubromazolam enhances inhibitory chloride conductance at the α/γ subunit benzodiazepine binding sitesupported
Benzodiazepine site at alpha/gamma subunit interface s41467-022-32212-4
No substance-specific binding affinity (Ki or EC₅₀) data have been published; quantitative structure-activity modelling predicts triazolobenzodiazepines as the most potent designer benzodiazepine subclasssupported
QSAR model to predict GABA-A receptor binding of newly emerging benzodiazepines including flubromazolam. Triazolobenzodiazepines predicted to be among the most potent group. j.scijus.2017.12.004
Flubromazolam carries low intrinsic pharmacotoxicity consistent with the benzodiazepine class, but acute risk is high: the sub-milligram active dose range creates a narrow margin between desired and dangerous effects, and synergistic respiratory depression with opioids drives nearly all documented fatalitiessupported
Illicit BZD deaths increased 519.6% 2019-2020. 92.7% with opioids. mmwr.mm7034a2
Tolerance develops rapidly — within days of continuous use — through GABA-A receptor subunit downregulation and compensatory glutamatergic sensitizationpartially supported
Tolerance mediated by GABA-A subunit downregulation and glutamatergic sensitization. ijms27031430
Physical dependence is severe; abrupt cessation carries seizure risk, and no established benzodiazepine equivalence conversion dose exists for clinical withdrawal managementsupported
seizure from abrupt cessation of multiple illicit substances including bromazolam/flubromazolam... Flubromazolam has no approved long-acting BZD equivalents; symptom-based diazepam management required. bcr-2025-266077
clinical-evidence7 · 7 ok
Huppertz and colleagues (2018) conducted a single-subject researcher self-experiment (0.5 mg oral) providing the only human pharmacokinetic data, including Tmax, half-life, and metabolite detection windows.supported
Self-experiment with 0.5 mg: terminal elimination half-life 10-20h, peak serum 8 ng/mL at 8h, urine detection up to 8 days dta.2203
Ellefsen and colleagues (2017) documented flubromazolam in a polydrug fatality case alongside 3-fluorophenmetrazine and U-47700, illustrating the polysubstance context in which flubromazolam-associated deaths typically occur.supported
Polydrug fatality case involving flubromazolam and delorazepam among other NPS. Cause of death: multiple drug toxicity. bkx060
The compound has no approved medical use in any jurisdiction and has never been the subject of systematic human pharmacological investigation beyond one researcher self-experiment.supported
Self-experiment with 0.5 mg: terminal elimination half-life 10-20h dta.2203
Łukasik-Głębocka and colleagues (2016) published the first clinical case — severe intoxication with prolonged coma, hypotension, and rhabdomyolysis following flubromazolam ingestion.supported
Flubromazolam is a new designer drug. Recreational use may be a cause of prolonged, severe intoxication associated with coma, hypotension, and rhabdomyolysis. 15563650.2015.1112907
Butler and colleagues (2025) reported a case of seizure following abrupt cessation of illicit benzodiazepines including flubromazolam; symptom-based management was required because no established benzodiazepine equivalence dose exists.supported
seizure from abrupt cessation... Flubromazolam has no approved long-acting BZD equivalents; symptom-based diazepam management required. bcr-2025-266077
US CDC surveillance data documented a 519.6% increase in illicit benzodiazepine-involved deaths (including flubromazolam) from 2019 to mid-2020; 92.7% of these deaths involved co-administered opioids.supported
Illicit BZDs (etizolam, flualprazolam, flubromazolam) increasingly detected in 2020. Illicit BZD deaths increased 519.6% 2019-2020. 92.7% with opioids. mmwr.mm7034a2
Papsun and colleagues documented increasing prevalence of flubromazolam in impaired driving cases over a five-year period (2017–2021), with CNS depressant impairment profiles confirmed in DUID evaluationssupported
1,145 DBZDs in 805 DUID blood samples 2017-2021. Flubromazolam detected among 11 DBZDs. Driving behavior consistent with CNS depressant effects. bkad036
history6 · 4 ok
The pivotal public health alert came from Moosmann, King, and Auwärter's 2015 letter in World Psychiatry, which identified flubromazolam alongside clonazolam as posing particular risk because compounds in this class "can cause strong sedation and amnesia at oral doses as low as 0.5 mg" — doses "extremely difficult to measure for users handling bulk materials, and tablets often vary greatly in the content of the active ingredient".partially supported
compounds like clonazolam or flubromazolam can cause strong sedation and amnesia at oral doses as low as 0.5 mg. Notes challenges with immunochemical detection and legal scheduling. wps.20236
Claim in history — inconclusiveinconclusiveworking →
Designer benzodiazepines as a class began appearing on online research chemical markets circa 2012supported
Since their first appearance on the Internet in 2012, designer benzodiazepines established as an additional, quickly growing compound class. dta.2203
Flubromazolam was first offered on internet markets from 2014 and was formally characterized in the peer-reviewed forensic toxicology literature by Huppertz, Bisel, Westphal, Franz, Auwärter, and Moosmann in 2015.partially supported
Flubromazolam offered online from 2014. dta.2203
The first published clinical case report, by Łukasik-Głębocka and colleagues in 2016, described a severe intoxication featuring prolonged coma, hypotension, and rhabdomyolysis, establishing flubromazolam as a life-threatening agent.supported
Flubromazolam is a new designer drug. Recreational use may be a cause of prolonged, severe intoxication associated with coma, hypotension, and rhabdomyolysis. 15563650.2015.1112907
Claim in history — inconclusiveinconclusiveworking →
comparative-pharmacology5 · 3 ok
Rat pharmacokinetic comparison with alprazolam (2 mg/kg subcutaneous) showed flubromazolam's volume of distribution and clearance were both approximately doubled, while elimination half-life was not significantly differentpartially supported
Flubromazolam displayed significant 2-fold increases in volume of distribution and clearance compared to alprazolam. Fluorination increases half-life and volume of distribution, leading to greater exposure and potential for greater toxicity than alprazolam. j.taap.2023.116459
Among designer benzodiazepines, flubromazolam is consistently grouped with clonazolam as having the highest potency — both produce significant pharmacological effects at 0.5 mg oral dosessupported
compounds like clonazolam or flubromazolam can cause strong sedation and amnesia at oral doses as low as 0.5 mg wps.20236
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
The substitution of bromine at C-8 (versus chlorine in triazolam) and fluorine on the pendant phenyl ring (versus chlorine in triazolam) appears to increase potency, as evidenced by pharmacological activity at sub-milligram oral doses.partially supported
compounds like clonazolam or flubromazolam can cause strong sedation and amnesia at oral doses as low as 0.5 mg wps.20236
neuroscience5 · 4 ok
Flubromazolam's effects arise from potentiation of GABAergic inhibitory neurotransmission at GABA-A receptors distributed throughout the central nervous systemsupported
Benzodiazepine site at alpha/gamma subunit interface. s41467-022-32212-4
Flubromazolam's effects arise from potentiation of GABAergic inhibitory neurotransmission at GABA-A receptors distributed throughout the central nervous systemsupported
BZDs act as GABA-A receptor positive allosteric modulators. s12991-025-00627-0
Claim in neuroscience — inconclusiveinconclusiveworking →
This anatomical co-localisation explains why the combination produces more-than-additive respiratory suppression.supported
BZD+opioid co-administration caused further decreases in PaO2 and increases in PaCO2 consistent with exacerbated respiratory depression. j.toxrep.2020.01.008
These include downregulation and internalisation of GABA-A receptor subunits (particularly α1), alterations in subunit gene expression, and compensatory upregulation of excitatory glutamatergic neurotransmission involving NMDA and AMPA receptor sensitisationsupported
Tolerance mediated by GABA-A subunit downregulation and glutamatergic sensitization. ijms27031430
chemistry2 · 0 ok
receptor-pharmacology2 · 2 ok
This class-level prediction is consistent with flubromazolam's observed pharmacological activity at sub-milligram doses — strong sedation and amnesia at 0.5 mg oral — but does not constitute substance-specific binding characterisation.supported
compounds like clonazolam or flubromazolam can cause strong sedation and amnesia at oral doses as low as 0.5 mg wps.20236
Waters and colleagues applied a quantitative structure-activity relationship (QSAR) model to predict GABA-A binding affinities across emerging designer benzodiazepines, concluding that triazolobenzodiazepines as a class exhibit the highest predicted potency among designer benzodiazepine structural subclassessupported
QSAR model to predict GABA-A receptor binding of newly emerging benzodiazepines including flubromazolam. Triazolobenzodiazepines predicted to be among the most potent group. j.scijus.2017.12.004
effects-overview1 · 1 ok
Relative to clonazolam — its closest comparator among designer benzodiazepines — flubromazolam appears to produce comparable potency per milligram but with a more prolonged and gradual onset, reflecting its distinct pharmacokinetic profile.partially supported
compounds like clonazolam or flubromazolam can cause strong sedation and amnesia at oral doses as low as 0.5 mg wps.20236